Furthermore, similar to the cocktail therapy for acquired immune deficiency syndrome, the combination of a commercially available RNA replication inhibitor and a SARS-CoV-2 cell entry inhibitor, such as KC and its derivatives, will be able to increase antiviral effectiveness, not only against the current SARS-CoV-2 strains, but also against mutant and resistant SARS-CoV-2 strains [53,54]. This evidence concerns the gene CALCA and AIDS.